1. Home
  2. RBBN vs PRTA Comparison

RBBN vs PRTA Comparison

Compare RBBN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ribbon Communications Inc.

RBBN

Ribbon Communications Inc.

HOLD

Current Price

$2.78

Market Cap

493.4M

Sector

Technology

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.84

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBBN
PRTA
Founded
1997
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.4M
539.9M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
RBBN
PRTA
Price
$2.78
$10.84
Analyst Decision
Strong Buy
Buy
Analyst Count
3
9
Target Price
$4.67
$19.00
AVG Volume (30 Days)
1.0M
342.8K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
170.97
N/A
EPS
N/A
0.60
Revenue
N/A
$814,000.00
Revenue This Year
$1.97
$1,111.38
Revenue Next Year
$6.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.83
$4.32
52 Week High
$4.29
$11.69

Technical Indicators

Market Signals
Indicator
RBBN
PRTA
Relative Strength Index (RSI) 57.82 52.77
Support Level $2.72 $9.81
Resistance Level $2.93 $11.61
Average True Range (ATR) 0.17 0.51
MACD -0.01 -0.07
Stochastic Oscillator 58.93 25.71

Price Performance

Historical Comparison
RBBN
PRTA

About RBBN Ribbon Communications Inc.

Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: